-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On November 3, Connoa announced that the CM326 clinical trial application was approved by the Food and Drug Administration for the treatment of atopic dermatitis
It is worth noting that the day before yesterday, Connoa just announced that the MASP-2 monoclonal antibody CM338 was approved for the first time for clinical research on the treatment of IgA nephropathy
Atopic dermatitis (AD) is a common chronic allergic skin disease.
TSLP is one of the initiating factors of the inflammatory cascade.
Source: Connoa Prospectus
Pre-clinical studies have shown that CM326 has good safety and excellent efficacy.
As of now, no TSLP monoclonal antibody has been approved for marketing globally